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Here, we report the isolation of a human multipotent adipose-derived stem (hMADS) cell 
population from adipose tissue of young donors. hMADS cells display normal karyotype; have 
active telomerase; proliferate 
 
 
 
200 population doublings; and differentiate into adipocytes, 
osteoblasts, and myoblasts. Flow cytometry analysis indicates that hMADS cells are CD44
 
 
 
, 
CD49b
 
 
 
, CD105
 
 
 
, CD90
 
 
 
, CD13
 
 
 
, Stro-1
 
 
 
, CD34
 
 
 
, CD15
 
 
 
, CD117
 
 
 
, Flk-1
 
 
 
, gly-A
 
 
 
, CD133
 
 
 
, 
HLA-DR
 
 
 
, and HLA-I
 
low
 
. Transplantation of hMADS cells into the mdx mouse, an animal 
model of Duchenne muscular dystrophy, results in substantial expression of human dystrophin 
in the injected tibialis anterior and the adjacent gastrocnemius muscle. Long-term 
engraftment of hMADS cells takes place in nonimmunocompromised animals. Based on the 
small amounts of an easily available tissue source, their strong capacity for expansion ex vivo, 
their multipotent differentiation, and their immune-privileged behavior, our results suggest 
that hMADS cells will be an important tool for muscle cell–mediated therapy.
 
Recently, multipotent adult stem cell popula-
tions have been obtained from various tissues
of human and rodent origin (1). Adult stem
cells can differentiate in vitro to cells of the
three germ layers and in vivo in tissue-specific
cells (2–5). For postnatal tissue-specific stem
cells to be used for the clinical treatment of de-
generated or inherited diseases, many criteria
must be fulfilled. These cells should be isolated
from a large reservoir of an easily available
source from human, and should ideally exhibit
the following: (a) long-term expansion in vitro
accompanied by normal karyotype; (b) multi-
lineage potential of a single cell in vitro, and
(c) capacity for long-term engraftment and tissue
regeneration after transplantation into recipi-
ents. Human mesodermal progenitor cells iso-
lated from bone marrow (human multipotent
adult progenitor cells [hMAPCs]) can be cul-
ture expanded 
 
 
 
70 population doublings
(PDs; reference 6). Given the medical implica-
tions, identification of hMAPCs has evoked
significant excitement. However, isolation of
bone marrow is frequently painful and yields
low doses of mesenchymal stem cells. White
adipose tissue (WAT) represents a major source
of expendable tissue. Stromal-vascular cells
from lipoaspirate (LPA) of human WAT have
been shown to contain multipotent stem cells,
but their ability to be maintained in culture
with a normal karyotype and to differentiate in
vivo remains unknown (7). We report herein
the isolation, from adipose tissue of young do-
nors, of a nonimmunogenic human multipo-
tent adipose-derived stem (hMADS) cell pop-
ulation that is able to undergo 
 
 
 
200 PDs and
to differentiate into cells of the adipogenic, os-
teogenic, and myogenic lineages as well as the
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characterization of derived clones. After transplantation into
muscles of the nonimmunocompromised mdx mouse, an
animal model of Duchenne muscular dystrophy, a long-term
engraftment occurs and a high proportion of the myofibers
expresses human dystrophin.
 
RESULTS
Isolation of a hMADS cell population
 
To isolate hMADS cells, first we modified the previous pub-
lished protocol used to isolate adipocyte precursors from the
stromal-vascular (SV) fraction (SVF) (see Materials and
methods). Next, we used the crude SVF of WAT from
young donors (1 mo-old to 7 yr-old) to avoid potential
aging effects on stem cell properties (8, 9). Two cell popula-
tions were isolated based on adhesion properties on un-
coated culture dishes. Fast-adherent (CA) cells and slow-
adherent (CS) cells were collected 12 and 72 h after plating,
respectively. At early passages, CA and CS cells showed sim-
ilar properties. Both exhibited a fibroblast-like morphology
and had a doubling time of 36 h. At this stage, CA and CS
cells were able to differentiate with a similar efficiency into
adipocytes and osteoblasts (Fig. 1 A). After 60–80 PDs,
marked changes were observed between the two popula-
tions. CS cells ceased to proliferate, lost their differentiation
properties (unpublished data), and exhibited senescence-
associated (SA) 
 
 
 
-galactosidase activity. In contrast, slow
growth (doubling time 
 
 
 
72 h) and flatness of CA cells oc-
curred whereas SA 
 
 
 
-galactosidase activity remained unde-
tectable (Fig. 1 B). CA cells expressed significant levels of te-
lomerase activity (23% of the activity of control HK 293T
cells), whereas CS cells showed no activity. To promote the
proliferation of CA and CS cells, various mitogens were
tested. Unlike hMAPCs (6), CA cells did not expand in re-
sponse to epithelial growth factor and/or platelet-derived
growth factor but responded to human fibroblast growth
factor (hFGF)-2. A strong proliferative response of CA cells
was obtained upon addition of this growth factor, in contrast
with the weak response of CS cells (Fig. 1, C and D). CA
cells were culture expanded 
 
 
 
200 PDs by passaging them
every 4–5 d. CA cells frozen and thawed after 3 and 18 mo
retained all the characteristics of the original population. CA
cells were named hMADS cells.
Using this technique, we were able to expand hMADS
cells from small pieces of adipose tissue (from 200 to 2,100
mg) of different anatomical sites of young donors of either
sex. As shown in Table I, of the six samples used in the ex-
periment, we succeeded in expanding hMADS cells beyond
150 PDs from four donors (hMADS-1, hMADS-2,
hMADS-3, and hMADS-6 cells). hMADS-4 and hMADS-5
cells were not studied beyond 40 and 20 PDs, respectively.
Figure 1. Isolation of cell populations and establishment of 
hMADS-2 cells. (A) In vitro differentiation of CA and CS cells at early 
passages (10 PDs). Cultures were stained after 15 d with Oil-red O for 
adipocytes and with Alizarin red for osteoblasts. (B) Cell morphology and 
SA  -galactosidase activity of CA and CS cells after 60 PDs. (C) Cell mor-
phology and (D) proliferative response of CA ( ,  ) and CS ( ,  ) cells in 
the absence ( ,  ) or the presence of 5 ng/ml hFGF-2 ( ,  ). 
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The karyotype of hMADS cells has been investigated (Fig. 2
A). Except for hMADS-4 cells that had an abnormal karyo-
type at 40 PDs, other hMADS cells did not show any karyo-
type abnormalities. No karyotype abnormalities were de-
tected for hMADS-2 cells at 70, 80, and 150 PDs; for
hMADS-1 and hMADS-3 cells at 90 PDs; and for hMADS-6
cells at 110 PDs. Of note, during isolation, both a quiescent
state and a reversible response to hFGF-2 were also observed
for hMADS-1 and hMADS-3 cells.
The phenotype of hMADS-2 cells at early (before 40
PDs) and late passages (between 80 and 160 PDs) was ana-
lyzed for cell surface markers (Fig. 2 B). In both cases, they
were Flk-1 (VEGF-R2), glycophorin A, CD34, CD15
(SSEA-I), CD117 (c-Kit), CD133, STRO-1 negative, and
CD13, CD49b, CD44, CD90 (Thy-1), and CD105 posi-
tive. The overlap of CD44 and CD49b curves with the neg-
ative control curve was due to a low expression of these two
antigens at the cell surface. After amplication of the signals,
which do not alter autofluorescence, the positive and nega-
tive histograms were clearly distinct (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20042224/DC1).
To show directly that hMADS-2 cells coexpressed the latter
markers, double staining experiments were performed. The
results demonstrate coexpression of CD105, CD44, CD49b,
and CD90 (Fig. S1). Importantly, hMADS-2 cells were both
class I HLA positive and class II HLA negative at early pas-
sages, but class I HLA low and class II HLA negative at late
passages; a similar phenotype was observed with hMADS-1
and hMADS-3 cells at early and late passages (unpublished
data).
 
hMADS cell differentiation into adipocytes, osteoblasts, 
and skeletal myocytes
 
The ability of hMADS-2 cells at 100 PDs to differentiate was
tested under conditions promoting different lineages (Fig. 3).
When exposed to adipogenic medium, 
 
 
 
90% of the cells
differentiated into adipose cells that were stained with Oil
red O for triglycerides (Fig. 3 A, left and middle) and ex-
pressed PPAR
 
 
 
2 and the adipocyte fatty acid-binding pro-
tein (aFABP) mRNAs specific of adipocytes (Fig. 3 A,
right). Differentiated cells underwent lipolysis in response to
 
 
 
1
 
- and 
 
 
 
2
 
-adrenoreceptor agonists and were able to secrete
adiponectin and leptin, whereas glycerol-3-phosphate dehy-
drogenase activities increased from 20–30 mU/mg to 1,000–
2,000 mU/mg (10). Osteogenesis occurred in the presence
of osteogenic medium as seen by alkaline phosphatase and
Alizarin red staining (Fig. 3 B, right and middle), and by de-
tection of matrix-associated calcium (not depicted). In con-
trast with cells maintained under adipogenic conditions,
these cells expressed reduced levels of PPAR
 
 
 
2 and aFABP
mRNAs, but instead expressed high levels of osteocalcin
mRNA (Fig. 3 B, right). When exposed to myogenic condi-
tions, immunochemical staining showed that cells expressed
myogenin, a transcription factor of myogenesis (Fig. 3 C,
left). Expression of MyoD1 and of desmin was also detected
(Fig. 3 C, right). Subsequently, flow cytometry analysis
showed that 
 
 
 
95% of the cells were fast-twitch myosin (Fig.
3 C, middle) and cell surface class I HLA positive (not de-
picted). However myotube formation was not observed.
Similar to hMADS-2 cells, hMADS-1, -3, and -6 cells dif-
ferentiated into adipose cells (10) and gave rise to osteoblasts
and myocytes (unpublished data).
Next, we wished to determine whether individual
hMADS cell clones could differentiate to different lineages.
For that purpose, clones were isolated by two different
methods; i.e., by limiting dilution from wild type and LacZ
genetically marked hMADS cells and by automated cloning
of enhanced GFP (EGFP)-positive cells sorted by FACS.
Figure 2. Characteristics of culture-expanded hMADS cells. (A) A 
representative result of cytogenetic analysis of hMADS-2 cells (n   3). 
(B) hMADS-2 cells cultured for 40 (early) or 160 (late) PDs (n   4) were 
labeled with FITC-conjugated antibodies against STRO-1, CD44, CD34, 
CD49b, CD15, CD105, and with PE-conjugated antibodies against CD90, 
CD117, CD13, Flk-1, Gly-A, CD133, class I-HLA, and HLA-DR or immuno-
globulin isotype control antibodies (n   4). Black line, control immuno-
globulins; red line, specific antibodies.
 
Table I.
 
Isolation of hMADS cells from different donors
 
Donor
age Sex
Anatomical
area
Sample
weight
SV
fraction
PDs
(CA cells)
Cell
population
 
mg cell no. 
 
 
 
 10
 
5
 
2 yr, 7 mo F umbilical 300 4
 
 
 
160 hMADS-1
5 yr M pubic 400 5
 
 
 
200 hMADS-2
4 mo M prepubic 210 4
 
 
 
160 hMADS-3
7 yr F inguinal 2,100 20 40 hMADS-4
1 mo F inguinal 200 3.5 20 hMADS-5
1 yr, 6 mo M scrotum 200 3.5
 
 
 
150 hMADS-6 
HUMAN MULTIPOTENT ADIPOSE-DERIVED STEM CELLS | Rodriguez et al.
 
1400
 
The hMADS-2 cell population, at 60 PDs, was first sub-
jected to classical limiting dilution. Starting after 2 wk of
culture, differentiation of 12 individual clones has been in-
vestigated. As shown in Table S1 (available at http://
www.jem.org/cgi/content/full/jem.20042224/DC1), 10
clones were bipotent and 2 were able to undergo differentia-
tion into adipocytes, osteoblasts, and myoblast-like cells. In a
separate experiment, hMADS cells have been transduced
with a lentiviral vector expressing nlsLacZ. After dilution
cloning, three LacZ-expressing clones were able to undergo
differentiation into adipocytes and osteoblasts. Southern blot
analysis has been performed and indicated that only one ret-
roviral insertion site was present and different for each clone
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20042224/DC1). In a third series of experiments,
hMADS cells were transduced with a lentivirus vector ex-
pressing EGFP. Then, EGFP-expressing cells were sorted by
FACS and cloned in an automated fashion. Three clones
were expanded and maintained in adipogenic and osteogenic
conditions. Data are summarized in Table S1. Altogether,
these data are in favor of the presence of single multipotent
cells in the hMADS cell population.
 
Cell engraftment and expression of human dystrophin 
in the mdx mouse
 
As hMADS cells differentiated in vitro into myocytes, we
determined whether these cells were able in vivo to express
human dystrophin in dystrophin-deficient mdx mice. The
finding that undifferentiated hMADS cells expressed low
levels of class I HLA and were class II HLA negative led us
to address the issue of immune-privileged behavior using
mdx mice treated or not with immunosuppressive drug (10
mg of cyclosporine A/kg, daily i.p. injection). hMADS-2
cells (1.5 
 
 
 
 10
 
5
 
), obtained after 160 PDs, were transplanted
in the left tibialis anterior muscle of 3-mo-old mdx mice. As
expected, no dystrophin-positive fibers were observed in the
Figure 3. In vitro differentiation of hMADS cells (80–120 PDs) to 
adipocytes, osteoblasts, and myoblasts. (A) Adipogenic differentiation. 
Confluent hMADS-2 cells before (day 0) and 15 d after treatment with 
adipogenic medium were stained with Oil red O for lipid droplets. RNAs 
were prepared and analyzed by RT-PCR for expression of PPAR 2 and 
aFABP. (B) Osteogenic differentiation. Confluent hMADS-2 cells before 
(day 0) and 15 d after treatment with osteogenic medium were stained 
with Alizarin red for bone nodules. At day 25 after osteogenic induction, 
cells were stained for alkaline phosphatase (AP) or with Alizarin red for 
bone nodules (BN). RNAs were prepared and analyzed by RT-PCR for ex-
pression of PPAR 2 and aFABP (adipocyte-specific genes) and osteocalcin 
(OC) (osteoblast-specific gene) in adipogenic (Ad.) and osteogenic (Os.) 
conditions. (C) Myogenic differentiation. Confluent hMADS-2 cells before 
(day 0) and 4 d after treatment with myogenic medium were stained for 
myogenin (Myog.). Fast-twitch myosin of permeabilized cells was detected 
by FACS 21 d after treatment with myogenic medium. RNAs were pre-
pared and analyzed by RT-PCR for expression of MyoD1 and desmin. 
(1) No RNA; (2) RNAs from undifferentiated hMADS cells; (3) RNAs from 
hMADS cells in myogenic medium for 4 d. 
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noninjected muscle other than the occasional revertant fibers
that represent not 
 
 
 
1% of the analyzed sections (Fig. 4 A, a).
In contrast, 10 d after transplantation, dystrophin was de-
tected in up to 50% of the myofibers analyzed on two con-
secutive sections. Dystrophin fibers were mainly organized
in clusters and no difference in the histological aspect and
number of dystrophin-positive myofibers was observed in
transplanted muscles of immunosuppressed or immunocom-
petent mdx mice (Fig. 4 A, b, b
 
 
 
, c, and c
 
 
 
). Similar results
were obtained 10 d after transplantation of hMADS-1 and
hMADS-3 cells in immunocompetent mdx mice (Table
S2, available at http://www.jem.org/cgi/content/full/
jem.20042224/DC1). Most of the dystrophin-positive fiber
sections contained both human and mouse nuclei as revealed
by DAPI and by fluorescent in situ hybridization analysis
when using a probe specific to human centromeres (Fig. 4 A,
b
 
 
 
 and c
 
 
 
). Human nuclei were also observed outside myo-
fibers (Fig. 4 A, b
 
 
 
). Nuclei were located both centrally and
at the periphery of the myofibers, indicating the existence of
regeneration and maturation processes. A higher proportion
of human versus murine nuclei was observed in injected
muscles (
 
 
 
70 vs. 
 
 
 
30% in dystrophin-positive myofibers).
Analysis of serial sections showed that dystrophin expression
was taking place all along the same myofiber. These results
strongly suggesting that hMADS cells were not rejected after
transplantation in tibialis anterior muscle, long-term engraft-
ment had been investigated in the absence of cyclosporin A
treatment. 50 d (Fig. 4 A, e and e
 
 
 
) and 80 d (Fig. 4 A, g) af-
ter transplantation of hMADS cells, we observed a time-
dependent pattern of dystrophin-positive myofibers. An in-
crease in the percentage of peripheral nuclei (outside and
within fibers) of human origin and a decrease in the percent-
age of central nuclei were observed from 10 to 50 d post-
transplantation (from 73 to 85% and from 27 to 15%, respec-
tively), providing evidence that injected cells participated in
the terminal differentiation of myofibers. Interestingly, the
presence of dystrophin-positive myofibers was observed in
the adjacent gastrocnemius muscle at 50 d (Fig. 4 A, f and f
 
 
 
)
and 80 d (Fig. 4 A, h). As this was not observed 10 d after
transplantation, this result indicates cell migration from the
injection site to other dystrophic muscles. 6 mo later, dystro-
phin was detected in up to 90% of the myofibers of trans-
planted tibialis anterior muscles. Serial cross sections indi-
cated a more homogeneous distribution of dystrophin than
at prior times (Fig. 4 A, i compared with Fig. 4 A, b, c, e,
and g). In contrast with tibialis anterior muscles of mdx mice
of the same age, necrotic myofibers were not observed, sug-
gesting a protective role of hMADS cells after long-term
transplantation (unpublished data). As expected, human dys-
trophin appeared located under the sarcolemna, in contrast
with mouse collagen III present between myofibers in the
extracellular space (Fig. 4 B, c–e).
To determine whether hMADS cells induce a prolifera-
tive response of lymphocytes in vitro, splenocytes from mdx
or from OF1 mice were cultured with irradiated hMADS
cells. No proliferation of mdx or OF1 splenocytes cultured
with hMADS cells was observed, in contrast with control
experiments that show that allogenic BALB/c splenocytes or
Figure 4. Human dystrophin and hMADS cells in skeletal muscle of 
mdx mice. (A) Expression of human dystrophin and detection of human 
nuclei 10 d (a–c), 50 d (d–f), 80 d (g and h), and 180 d (i) after transplanta-
tion of hMADS-2 cells. Human nuclei (nuclei counterstained with DAPI in 
blue and human centromeres as red hybridization signals) were found present 
within dystrophin-positive myofibers (green) and also at the periphery of 
myofibers using dystrophin antibody NCL-DYS2. (a, a , d, d ) Right tibialis 
anterior muscle (control); (b, b ) left tibialis anterior muscle of cyclosporin 
A–treated mdx mice; (c, c , e, e ) left tibialis anterior muscle of immuno-
competent mdx mice; (f, f ), left gastrocnemius muscle of immunocompe-
tent mdx mice; g, Left tibialis anterior muscle; h, left gastrocnemius; i, left 
tibialis anterior muscle. Bar, 20  m (a–c, d–f, g–i) and 5  m (a –c , d –f ). 
(B) Dystrophin-positive myofibers and dystrophin subcellular localization 
were analyzed in the tibialis anterior muscle 10 d after transplantation 
using antibodies directed against (c, e) NH2 terminus of human dystrophin 
and (d, e) mouse collagen III. Bars, 1  m. 
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xenogenic human peripheral blood lymphocytes induced
proliferation of mdx or OF1 splenocytes (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20042224/DC1).
Consistent with an absence of an immune recognition,
transplantation of hMADS cells did not lead within 10 d to
infiltration by mCD3-positive lymphocytes (Fig. 5, b and b
 
 
 
)
nor at 50 and 80 d after transplantation (not depicted). In
contrast, transplantation of the same number of CA or CS
cells at early passage (40 PDs), which expressed high levels of
class I HLA (Fig. 2 B), did not restore dystrophin expression
in muscle of mdx mice (not depicted) and elicited a strong
immune response (Fig. 5, c and c
 
 
 
). Similar observations
were made with SV cells at 10 PDs without prior separation
of CA and CS cells.
 
DISCUSSION
 
In the present study, we isolated, independently of sex and
adipose depot of young donors, a population of cells that
could be extensively expanded ex vivo and that could un-
dergo differentiation into various cell types. Our method
took advantage of the extensive lifespan of stem cells as com-
pared with other cell types. hMADS cells were generated
from adipose tissue of young donors. Whether hMADS cells
also can be generated from older persons has not been tested.
hMADS cells shared many properties described for hMAPCs
(extensive expansion capacity in vitro, clonal multilineage
differentiation potential, telomerase activity with normal
karyotype; references 5, 6), but differed with respect to (a)
their maintenance in 10% serum-supplemented medium
with no loss of their differentiation potential after 200 PDs;
(b) expression of cell surface markers revealed by immu-
nophenotypic analysis; and (c) their response to various
growth factors and extracellular matrix components. In addi-
tion, hMADS cells are easy to isolate and to expand. Frozen
and thawed cells kept the same characteristics than the origi-
nal population. The hMADS cell population contained sin-
gle cells able to differentiate in vitro into mesodermal lin-
eages. The hMADS cells were obtained after 160–200 PDs
and differed clearly from SV cells (11), adipose tissue–
derived stromal cells (12), and processed LPA cells (7), which
were studied at either the first (7, 11) or the second to third
passage (i.e., after a few PDs; reference 12). Although the
population of LPA cells exhibited multipotency (7, 13), the
coexistence at that stage of single lineage and multiple lin-
eage–committed progenitor cells was not ruled out. More-
over, among clones exhibiting differentiation into mesoder-
mal lineages, differentiation into myocytes was not reported.
In contrast with LPA cells, hMADS cells expressed high lev-
els of cell surface CD105 and did not express STRO-1. Fur-
thermore, expression of class I and class II HLA and regener-
ative properties in vivo were not reported for LPA cells.
When injected into mdx mice, hMADS cells gave rise
to higher levels of dystrophin-positive myofibers than pre-
viously reported for primary myoblasts or muscle stem cells
isolated from wild-type mice (14), indicating substantial re-
cruitment of hMADS cells to the dystrophic muscle. Inter-
estingly, in wild-type mice suffering from partial muscle ne-
crosis after bupivacain treatment, hMADS cells did not
induce after 10 d a detectable expression of human dystro-
phin in the transplantated tibialis anterior muscle despite the
presence of human nuclei in the regenerating zone (unpub-
lished data). Thus, the apparent selective advantage of
hMADS cells appears related to the inefficiency of mdx sat-
ellite cells to generate mature and stable myofibers. Re-
markably, hMADS cells were able to migrate within 50 d
from the tibialis anterior to the adjacent gastrocnemius mus-
cle. This spatial-temporal regenerative behavior of the cells
suggests a possible delivery of dystrophin to other skeletal
muscles and the restoration of a normal phenotype includ-
ing reduced necrosis. Based on this, hMADS cells could be
considered as alternative cell source for muscle replacement
therapy. Two mechanisms can be suggested to account for
the contribution of hMADS cells to muscle regeneration:
de novo generation of muscle-specific cells from hMADS
cells or changes in gene expression after direct fusion of
hMADS cells with host cells. Preliminary data suggest that
the muscle phenotype of hMADS cells after transplantation
may be acquired through both commitment into the myo-
genic lineage and direct cell fusion as nuclei of hMADS
cells could fuse spontaneously with unidentified host cell
nuclei at a high rate 7 d after transplantation. The relative
contribution of transdifferentiation versus nuclear fusion in
the long-term engraftment of hMADS cells into the muscle
remains to be investigated.
Figure 5. Absence of infiltration by mCD3-positive lymphocytes 
in muscle of immunocompetent mdx mice after transplantation with 
hMADS cells. Staining was performed with hematoxylin (a–c) or with anti-
bodies against mouse CD3 (a , c ); left tibialis anterior muscle nontrans-
planted (a, a ) or 10 d after transplantation of hMADS-2 cells (b, b ) (n   8) 
and CA cells at 40 PDs (c, c ) (n   5). Bar, 50  m (a–c) and 20  m (a –c ).JEM VOL. 201, May 2, 2005 1403
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The cells display an immunoprivileged behavior and
were not rejected in nonimmunocompromised mdx mice
up to 6 mo after transplantation. The absence of an immune
recognition may be due in part to the low level of cell sur-
face class I and the absence of class II HLA, similar to the
lack of allogenic rejection in mdx mice reported for (MHC)
class I–negative muscle stem cells (15). Nevertheless, our
observations obviously raise a serious immunological chal-
lenge as (a) class I HLA expression should be increased in
vivo during the formation of dystrophin-positive myofibers
as it is the case for hMADS cells in vitro under myogenic
conditions and (b) human dystrophin is expressed at high
levels in mdx mice despite the fact that it has been reported
to elicit potent cytotoxic and humoral immune responses
(16, 17). The immunoprivileged behavior of hMADS cells
is reinforced by the lack of recognition by T lymphocytes,
as shown by the absence of infiltration by mCD3 positive
cells. The mechanisms by which hMADS cells escape im-
mune surveillance remain unclear. When present outside
the myofibers, these cells could facilitate the reeducation of
the recipient immune system as suggested for rat embryonic
stem-like cells (18). Alternatively, or in addition, hMADS
cells could exhibit immunosuppressive properties, as re-
cently described for mesenchymal multipotent stem cells
from human and mouse bone marrow (19, 20). Such im-
munosuppression is likely to occur via the production of
cytokines, such as IL-4, IL-10, and TGF , responsible for
the inhibition of alloreactive lymphocyte proliferation (21).
Gene expression analysis indicate that hMADS cells do not
express either IL-4 or IL-10 but express TGF 1, TGF 2,
and TGF 3 (unpublished data). Whether TGF  may con-
trol the immunosuppression induced by hMADS cells has
still to be demonstrated.
Together, the properties of hMADS cells, combined
with the small amount of an easily available tissue needed for
their isolation make these cells a suitable tool for autologous
and heterologous transplantation in humans. Autologous
transplantation combined with gene therapy has often led to
deleterious immune responses, in particular in Duchenne
muscular dystrophy patients (22). In this context, the non-
immunogenic and regenerative properties of hMADS cells
hold great promise with respect to this pathology and other
inherited diseases.
MATERIALS AND METHODS
Isolation of hMADS cells. For the isolation of hMADS cells from young
donors, adipose tissue was obtained with the informed consent of the parents
as surgical scraps from surgical specimen of various surgeries, as approved by
the Centre Hospitalier Universitaire de Nice Review Board. We modified a
previous published protocol used to isolate adipocyte precursors from adi-
pose tissue (23). In brief, 200 mg/ml adipose tissue was dissociated for 5–10
min in DMEM containing antibiotics (100 U/ml of penicillin and 100  g/
ml of streptomycin), 2 mg/ml collagenase, and 20 mg/ml bovine serum-
albumin. The crude SVF was separated from the adipocyte fraction by low
speed centrifugation (200 g, 10 min). The adipocyte fraction was discarded
and cells from the pelleted SVF were seeded onto uncoated tissue culture
plates (Greiner) at 1,000–3,500 cells/cm2 in low glucose DMEM (Invitro-
gen) supplemented with 10% heat-inactivated fetal bovine serum (D. Dutsch-
ers) and antibiotics as described before. Fast-adherent cells, termed CA cells,
were separated from slow-adherent cells, termed CS cells. CA and CS cells
were expanded in the same culture medium as described before. After reach-
ing 70% confluence, cells were dissociated (0.25% trypsin EDTA; Invitro-
gen) and replated at 1,000–3,000 cells/cm2. Telomerase activity was deter-
mined by means of TeloTAGGG Telomerase PCR ElisaPLUS kit from
Roche Diagnostic, according to the manufacturer’s recommendations. SA
 -galactosidase activity was determined according to Dimri et al. (24).
Karyotyping.  Dividing cells at various PDs were arrested in metaphase with
colcemid overnight, hypotonically shocked with KCl, and fixed with metha-
nol/acetic acid (3/1; vol/vol). Chromosomes were identified using RHG-
banding technique. At least 30 mitoses were examined for each karyotype.
hMADS cell differentiation. For adipocytes, confluent cells were cul-
tured in DMEM/Ham’s F12 media supplemented with 10  g/ml transfer-
rin, 100  M ascorbic acid 2-sodium, 0.85  M insulin, 20 nM sodium se-
lenite, 0.2 nM triiodothyronine, 1  M dexamethasone (DEX), 100  M
isobutyl-methylxanthine and 1  M rosiglitazone. 3 d later, the medium was
changed (DEX and isobutyl-methylxanthine were omitted). Neutral lipid
accumulation was assessed by Oil red O staining and glycerol-3-phosphate
dehydrogenase activity assays were performed as previously described (25).
For osteoblasts, confluent cells were cultured in 10% FCS supplemented
with 0.1  M DEX, 10 mM  -glycerophosphate, and 50  g/ml ascorbic
acid 2-phosphate. Alkaline phosphatase and Alizarin red staining were per-
formed as previously described (26), and matrix-associated calcium was de-
termined using a commercial detection kit (Sigma-Aldrich). For myocytes,
confluent cells were maintained in Skeletal Muscle Cell Differentiation me-
dium (PromoCell). Myogenin and fast-twitch myosin expression was deter-
mined at indicated times.
Immunocytochemistry analysis. Cells were fixed with 4% paraformal-
dehyde for 15 min and permeabilized with PBS/0.1% Triton X-100. En-
dogenous peroxidase activity was quenched with 3% hydrogen peroxide for
10 min. Slides were incubated sequentially for 1 h with mouse monoclonal
antimyogenin (1:100) and anti–mouse IgG antibodies and for 10 min with
3,3 -diaminobenzidine (Vector Laboratories). Antibodies against myogenin,
fast-twitch myosin, control mouse, and goat IgGs were obtained from Santa
Cruz Biotechnology, Inc.
Flow cytometric analysis. Cells were detached and treated sequentially
with primary antibodies and, if necessary, immunofluorescent secondary an-
tibodies were then fixed with 1% formaldehyde until analysis with a FACS-
Calibur (Becton Dickinson). Antibodies against human CD105 and second-
ary anti–mouse antibody conjugated with FITC were obtained from R&D
Systems and Caltag, respectively. Phycoerythrin (PE)-conjugated antibody
against human CD133 was obtained from R&D Systems, and those against
human CD13, CD90, CD117, class I HLA, HLA-DR, Flk1, glycophorin
A, and isotype control were obtained from BD Biosciences. FITC-conju-
gated antibodies against human CD15, CD34, CD44, CD49b, and isotype
control were obtained from BD Biosciences. Antibody against STRO-1
was obtained from R&D Systems and secondary anti–mouse IgM antibody
conjugated with FITC was obtained from BD Biosciences. Amplification of
positive signals was performed by adding FITC-labeled rabbit anti–mouse
IgG (Caltag) after CD44 and CD49b staining. For detection of intracellular
fast-twitch myosin, cells were previously fixed with 1% paraformaldehyde
in phosphate-buffered saline and permeabilized with 10  g/ml of digitonin
for 7 min at 20 C. Fast-twitch myosin was labeled with PE-conjugated spe-
cific antibodies and analyzed by FACS.
Reverse transcription PCR analysis.  Total RNA was isolated using
Tri agent (Euromedex), according to manufacturer’s instructions, separated
by gel electrophoresis, blotted on Hybond N , and hybridized with specificHUMAN MULTIPOTENT ADIPOSE-DERIVED STEM CELLS | Rodriguez et al. 1404
radiolabeled probes (ICN Biomedicals) using the ready-prime TM II Ran-
dom Prime Labeling system (Amersham Biosciences). The primers used for
PCR amplification and hybridization (internal primers) were: aFABP,
forward, 5 -GCTTTGCCACCAGGAAAGTG-3 , and reverse, 5 -ATG-
ACGCATTCCACCACCAG-3 , internal primer, 5 -TGCAGTGACTT-
CGTCAAATT-3  for a 280-bp fragment; osteocalcin, forward, 5 -CGC-
AGCCACCGAGACACCAT-3 , and reverse, 5 -GGGCAAGGGCAA-
GGGGAAGA-3 , internal primer, 5 -GCTGCCCTCCTGCTTAA-3  for
a 320-bp fragment; MyoD1, forward, 5 -AAGCGCCATCTCTTGAG-
GTA-3 , and reverse, 5 -GCGCCTTTATTTTGATCACC-3 , for a frag-
ment of 490 bp; desmin, forward 5 -CCTACTCTGCCCTCAACTTC-
3 , and reverse 5 -AGTATCCCAACACCCTGCTC-3  for a fragment of
519 bp; and  -actin, forward, 5 -CCGACAGGATGCAGAAGGAG-3 ,
and reverse, 5 -GGCACGAAGGCTCATCATTC-3  for a fragment of
662 bp.
Transplantation of hMADS cells into mdx mice. C57BL/10ScSN-
Dmdmdx/J (X-linked muscular dystrophy) mice were obtained from Charles
River Laboratories. 3-mo-old mdx mice were injected with 1.5   105
hMADS cells resuspended in 50  l of HBSS (Invitrogen) in the left tibialis
anterior muscle. 50  l of HBSS were injected in the right tibialis anterior
muscle used as control. Both muscles and adjacent gastrocnemius muscles
were removed and snap frozen in isopentane precooled in liquid nitrogen.
Cryostat serial sections of 12  m were prepared from frozen muscles. Animal
experiments were performed in accordance with the recommendations of
the French Accreditation of the Laboratory Animal Care and were approved
by the local Centre National de la Recherche Scientifique ethics committee.
Analysis of hMADS cells engraftment and human dystrophin
expression. The human origin of dystrophin was demonstrated by com-
parative immunodectection using antibodies against mouse and human dys-
trophin at the COOH terminus and against human dystrophin at the NH2
terminus, which gave similar results. Antibodies against NH2 terminus of
human dystrophin (NCL-DYS3) or directed toward COOH terminus of
human and mouse dystrophin (NCL-DYS2) were obtained from Novocas-
tra. Before use, NCL-DYS2 and NCL-DYS3 were conjugated using, re-
spectively, Zenon Alexa Fluor 488 mouse IgG1 and Zenon Alexa Fluor 488
mouse IgG2 labeling kit (Interchim). Antibody against mouse collagen type
III and secondary goat anti–rabbit Alexa 568 antibody were obtained from
Rockland and Interchim, respectively. FITC-conjugated antibody against
mouse CD3 was obtained from BD Biosciences. For fluorescent in situ hy-
bridization analysis and colocalization with dystrophin-positive myofibers, a
digoxigenin-labeled all human centromere probe ( -satellite) was used. De-
tection was performed with rhodamine-labeled antidigoxigenin antibodies
(Quantum Appligen). Samples were counterstained with DAPI and slides
were examined using a Zeiss Axiophot fluorescent microscope.
For double staining, sections were incubated with mouse collagen III
antibody, followed by incubation with Alexa 568 secondary antibody, be-
fore proceeding to dystrophin detection as described before. For mapping
regeneration or infiltration zones, 1 section out of 50 sections was stained
with Harris’ hematoxylin, rinsed with water, and dehydrated with ethanol
(50, 75, and 100%) for 10 min. For single staining, frozen sections were first
fixed with methanol/acetic acid (75/25 vol/vol) at  20 C for 15 min. All
the following steps were performed at room temperature. Subsequently, af-
ter incubation for 1 h with mCD3 antibody labeled with FITC, sections
were mounted with antifading solution to be visualized on an Olympus
BH2 epifluorescence microscope.
Online supplemental material. Fig. S1 shows the coexpression of
CD90, CD49b, CD44, and CD105 by FACS analysis. Table S1 and Fig. S2
include additional data on the cloning of hMADS cells. Fig. S3 shows the
effect of hMADS cells on the proliferation of OF1 and mdx splenocytes.
Table S2 includes additional data on the transplantation of hMADS cells in
mdx mice. Materials and methods for the cloning of hMADS cells and the
assay for proliferation of OF1 and mdx splenocytes are available, in addition
to all the other supplemental material, online at http://www.jem.org/cgi/
content/full/jem.20042224/DC1.
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